Cencora, Inc.
CORNYSE · SIC 5122
$307.90
↓ -0.0%Jul 17 close · end-of-day
Price
1Y↑ +4.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$60.2B
Enterprise Value
$70.4B
P/E
23.6
P/S
0.2
P/B
17.7
EV/EBITDA
18.5
PEG
—
FCF Yield
2.6%
Dividend Yield
0.8%
Revenue (TTM)
$328.7B
Net Income (TTM)
$2.5B
Free Cash Flow (TTM)
$1.6B
Gross Margin
3.8%
Operating Margin
0.9%
Net Margin
0.8%
ROE
75.0%
ROIC
14.9%
Debt / Equity
3.6
Net Cash
-$10.2B
Return 1Y
+5.4%
Company profile
Cencora, Inc. sources and distributes pharmaceutical products. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
- CEO
- Steven H. Collis
- Sector
- Wholesale Trade
- Industry
- Wholesale
- Employees
- 42,000
- Headquarters
- Pennsylvania
- Website
- www.cencora.com
Management & directors
- Battaglia SilvanaExecutive Vice President
- Campbell Elizabeth SExecutive Vice President
- Cleary James F JrChief Financial Officer
- Mauch Robert P.President & CEO
- Krikorian LazarusSVP & Chief Accounting Officer
- Verma PawanEVP, Chief Data & Info Officer
- Collis Steven HExecutive Chairman
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-05
COR Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$78.4B↑ +3.8%
Diluted EPS$8.40↑ +128.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $189.9B | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Gross profit | $5.2B | $6.9B | $8.3B | $9.0B | $9.9B | $11.5B |
| Operating income | -$5.1B | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B |
| Net income | -$3.4B | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| Diluted EPS | -$16.65 | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Operating cash flow | $2.2B | $2.7B | $2.7B | $3.9B | $3.5B | $3.9B |
| Free cash flow | $1.8B | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Gross margin | 2.7% | 3.2% | 3.5% | 3.4% | 3.4% | 3.6% |
| Operating margin | -2.7% | 1.1% | 1.0% | 0.9% | 0.7% | 0.8% |
| Net margin | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.2B | $79.1B | $81.5B | $75.5B | $80.7B | $83.7B | $85.9B | $78.4B |
| Gross profit | $2.4B | $2.5B | $2.6B | $3.1B | $2.9B | $3.0B | $3.1B | $3.6B |
| Operating income | $672.5M | $126.6M | $706.3M | $1.0B | $867.7M | $18.5M | $760.4M | $1.1B |
| Net income | $483.5M | $3.4M | $488.6M | $717.9M | $687.4M | -$339.7M | $559.6M | $1.6B |
| Diluted EPS | $2.42 | $0.04 | $2.50 | $3.68 | $3.52 | -$1.74 | $2.87 | $8.40 |
| Operating cash flow | $2.5B | $1.0B | -$2.7B | $3.4B | $109.2M | $3.1B | -$2.3B | $1.3B |
| Free cash flow | $2.4B | $818.1M | -$2.8B | $3.2B | -$74.0M | $2.9B | -$2.4B | $1.2B |
| Gross margin | 3.2% | 3.2% | 3.1% | 4.1% | 3.6% | 3.5% | 3.6% | 4.6% |
| Operating margin | 0.9% | 0.2% | 0.9% | 1.4% | 1.1% | 0.0% | 0.9% | 1.5% |
| Net margin | 0.7% | 0.0% | 0.6% | 1.0% | 0.9% | -0.4% | 0.7% | 2.1% |
Company news
Jul 13, 2026
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Battaglia Silvana· Executive Vice President | Award | 58 | $240.53 | $13,999.98 | filing |
| 2026-06-30 | Campbell Elizabeth S· Executive Vice President | Award | 50 | $240.53 | $11,999.95 | filing |
| 2026-06-22 | Tyler Lauren M | Buy | 550 | $270.23 | $148,626.50 | filing |
| 2026-06-18 | DURCAN DERMOT MARK | Buy | 4,000 | $274.19 | $1.1M | filing |
| 2026-05-28 | DURCAN DERMOT MARK | Buy | 4,000 | $266.26 | $1.1M | filing |
| 2026-05-01 | NALLY DENNIS M | Award | 116 | $304.00 | $35,264.00 | filing |
| 2026-05-01 | Tyler Lauren M | Award | 99 | $304.00 | $30,096.00 | filing |
| 2026-05-01 | Cooper Ellen | Award | 99 | $304.00 | $30,096.00 | filing |
| 2026-03-11 | Campbell Elizabeth S· Executive Vice President | Tax withholding | 5,842 | $350.30 | $2.0M | filing |
| 2026-03-11 | Cleary James F JR· Chief Financial Officer | Tax withholding | 5,409 | $350.30 | $1.9M | filing |
| 2026-03-11 | Battaglia Silvana· Executive Vice President | Tax withholding | 3,673 | $350.30 | $1.3M | filing |
| 2026-03-11 | Cleary James F JR· Chief Financial Officer | Option exercise | 12,623 | $0.00 | $0.00 | filing |
| 2026-03-11 | Battaglia Silvana· Executive Vice President | Option exercise | 8,415 | $0.00 | $0.00 | filing |
| 2026-03-11 | Campbell Elizabeth S· Executive Vice President | Option exercise | 12,623 | $0.00 | $0.00 | filing |
| 2026-03-05 | DURCAN DERMOT MARK | Award | 905 | $359.28 | $325,148.40 | filing |
| 2026-03-05 | GREENBERG LON R | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Kim Lorence H. | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Miller Redonda | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Ryerkerk Lori | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Clyburn Frank | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Cooper Ellen | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | NALLY DENNIS M | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Tyler Lauren M | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-03-05 | Baumann Werner | Award | 557 | $359.28 | $200,118.96 | filing |
| 2026-02-20 | Mauch Robert P.· President & CEO | Sale | 3,762 | $358.94 | $1.4M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.